DR US

The chart shows the growth of an initial investment of $10,000 in DR US, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

As of Jun 13, 2026, the DR US returned 12.95% Year-To-Date and 15.74% of annualized return in the last 10 years.

Based on dividend-adjusted daily data since Jun 30, 2014, DR US's average daily return is +0.05%, while the average monthly return is +1.10%. At this rate, an investment would double in approximately 5.3 years.

Historically, 68% of months were positive and 32% were negative. The best month was Apr 2020 with a return of +12.3%, while the worst month was Mar 2020 at -11.6%. The longest winning streak lasted 15 consecutive months, and the longest losing streak was 3 months.

On a daily basis, DR US closed higher 56% of trading days. The best single day was Nov 16, 2023 with a return of +11.2%, while the worst single day was Nov 17, 2023 at -10.3%.

DR US has an annualized alpha of 5.40%, beta of 0.67, and R2 of 0.48 versus S&P 500 Index. Calculated based on daily prices since June 30, 2014.

• This portfolio captured 104.47% of S&P 500 Index gains but only 98.67% of its losses - a favorable profile for investors.
• Beta of 0.67 may look defensive, but with R2 of 0.48 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R2 of 0.48 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.

DR US has an expense ratio of 0.26%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

DR US ranks 73 for risk / return — better than 73% of Portfolios on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

The current DR US Sharpe ratio is 2.31 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.54 to 2.41, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of DR US compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

DR US provided a 0.55% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the DR US. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the DR US was 33.43%, occurring on Mar 23, 2020. Recovery took 93 trading sessions.

The current DR US drawdown is 1.62%.

The chart below shows the rolling one-month volatility.